Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).

Evaristo Maiello,Gabriele Di Maggio,S. Cordio,Saverio Cinieri,Francesco Giuliani,Salvatore Pisconti,Antonio Rinaldi,Antonio Febbraro,Tiziana Latiano,Michele Aieta,D. Rizzi,Massimo Di Maio,Giuseppe Colucci,Roberto Bordonaro

Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).

2018

Evaristo Maiello
Gabriele Di Maggio
S. Cordio
Saverio Cinieri
Francesco Giuliani
Salvatore Pisconti
Antonio Rinaldi
Antonio Febbraro
Tiziana Latiano
Michele Aieta
D. Rizzi
Massimo Di Maio
Giuseppe Colucci
Roberto Bordonaro

3542Background: B plus bi-weekly FOLFOX4 or three-weekly XELOX represents a standard 1-line therapy for mCRC pts. In our previous phase II study (Fedele P et al, ASCO 2009) we demonstrated a simila...

Keywords:

Bevacizumab
Capecitabine
Physical therapy
Colorectal cancer
Oxaliplatin
Medicine
Cancer research
Phases of clinical research
Oncology
Internal medicine
Pathology
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations